azacitidine has been researched along with tamoxifen in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.55) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 6 (27.27) | 29.6817 |
| 2010's | 13 (59.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hansch, C; Khwaja, TA; Selassie, CD | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brunner, KW; Cavalli, F | 1 |
| Dekker, A; Dorssers, LC; Foekens, JA; van Agthoven, T; van Agthoven, TL | 1 |
| Jiang, J; Peng, ZH; Tang, B | 1 |
| Davidson, NE; Saxena, NK; Sharma, D; Vertino, PM | 1 |
| Fan, QX; Li, LW; Lu, SH; Wang, LX; Wang, R; Wang, RL; Zhao, PR | 1 |
| Di, GH; Fan, J; Lu, JS; Shao, ZM; Shen, ZZ; Wang, L; Wu, FY; Wu, J; Yin, WJ | 1 |
| Hostetter, CL; Keen, JC; Licata, LA | 1 |
| Jagodzinski, PP; Lianeri, M; Lutkowska, A; Pietkiewicz, PP | 1 |
| Ahn, SG; Kang, KW; Kim, HS; Kim, SK; Kim, TH; Lee, KY; Lim, SC; Phuong, NT; Yoon, JH | 1 |
| Artemov, D; Carraway, H; Domek, J; Kato, Y; Kimble, B; Kowalski, J; Lisok, A; Raman, V; van der Groep, P; van Diest, P; Vesuna, F | 1 |
| D'Costa, ZJ; Hibma, MH; Leong, CM; Matthews, C; Shields, J | 1 |
| Dutkowski, C; Farrow, L; Fiegl, H; Gee, JM; McClelland, RA; McCloy, RA; Musgrove, EA; Nicholson, RI; Stone, A; Sutherland, RL; Valdés-Mora, F | 1 |
| Chen, H; Hardy, TM; Li, Y; Meeran, SM; Patel, SN; Tollefsbol, TO | 1 |
| Charalambous, C; Constantinou, AI; Papageorgis, P; Pitta, CA | 1 |
| Anderton, DL; Arcaro, KF; Lee, MP; Pentecost, BT; Williams, KE | 1 |
| Gun, M; Hong, XY; Wang, Q | 1 |
1 review(s) available for azacitidine and tamoxifen
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for azacitidine and tamoxifen
| Article | Year |
|---|---|
[New substances in oncologic therapy].
Topics: Altretamine; Ancitabine; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Cisplatin; Clinical Trials as Topic; Dacarbazine; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Etoposide; Humans; Mitolactol; Nitrosourea Compounds; Razoxane; Remission, Spontaneous; Tamoxifen; Time Factors; Vinca Alkaloids; Zinostatin | 1978 |
20 other study(ies) available for azacitidine and tamoxifen
| Article | Year |
|---|---|
Structure-activity relationships of antineoplastic agents in multidrug resistance.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Survival; Cricetinae; Dactinomycin; Drug Resistance; Leukemia L1210; Mice; Regression Analysis; Structure-Activity Relationship; Tumor Cells, Cultured | 1990 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations.
Topics: Azacitidine; Breast Neoplasms; Down-Regulation; ErbB Receptors; Estradiol; Estrogen Antagonists; Estrogens; Female; Gene Expression Regulation, Neoplastic; Humans; Keratins; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Polyunsaturated Alkamides; Proteins; Receptor, ErbB-2; Receptors, Estradiol; Receptors, Progesterone; Tamoxifen; Trefoil Factor-1; Tumor Cells, Cultured; Tumor Suppressor Proteins | 1994 |
[The synergistic inhibitory effect of 5-aza-2-deoxycytidine and Tamoxifen on estrogen receptor alpha negative breast cancer cell lines in vitro].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Decitabine; Drug Synergism; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen | 2005 |
Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Drug Synergism; Estrogen Antagonists; Estrogen Receptor alpha; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Mi-2 Nucleosome Remodeling and Deacetylase Complex; Promoter Regions, Genetic; Repressor Proteins; RNA, Messenger; Sin3 Histone Deacetylase and Corepressor Complex; Tamoxifen | 2006 |
[Demethylation of estrogen receptor gene and its re-expression in estrogen receptor-negative breast].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Azacitidine; Base Sequence; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Promoter Regions, Genetic; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Selective Estrogen Receptor Modulators; Tamoxifen | 2006 |
ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor.
Topics: Animals; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mice; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Trefoil Factor-1; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2008 |
Timing is everything: order of administration of 5-aza 2' deoxycytidine, trichostatin A and tamoxifen changes estrogen receptor mRNA expression and cell sensitivity.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; Drug Administration Schedule; Estrogen Receptor Modulators; Humans; Hydroxamic Acids; Receptors, Estrogen; RNA, Messenger; Tamoxifen | 2009 |
Tamoxifen epigenetically modulates CXCL12 expression in MCF-7 breast cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Chemokine CXCL12; Cytosine; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Sequence Analysis, DNA; Tamoxifen | 2010 |
Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Resistance, Neoplasm; Enzyme Activation; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Promoter Regions, Genetic; PTEN Phosphohydrolase; S-Adenosylmethionine; Tamoxifen; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α.
Topics: Acetylation; Animals; Antineoplastic Agents; Azacitidine; Breast Neoplasms; Capillary Permeability; Cell Line, Tumor; Chromatin; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Down-Regulation; Drug Resistance, Neoplasm; E-Box Elements; Estrogen Receptor alpha; Estrogens; Female; Histone Deacetylase 1; Histones; Humans; Mice; Nuclear Proteins; Promoter Regions, Genetic; Protein Transport; RNA, Small Interfering; Tamoxifen; Twist-Related Protein 1; Valproic Acid | 2012 |
Screening of drugs to counteract human papillomavirus 16 E6 repression of E-cadherin expression.
Topics: Antiviral Agents; Azacitidine; Cadherins; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Methylation; Doxorubicin; HCT116 Cells; Humans; Indoles; Oncogene Proteins, Viral; Repressor Proteins; Tamoxifen | 2012 |
Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer.
Topics: Apoptosis; Azacitidine; Breast Neoplasms; Cell Proliferation; DNA Methylation; Drug Resistance, Neoplasm; ErbB Receptors; Estrogens; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Neoplasm; Growth Differentiation Factor 15; Humans; MCF-7 Cells; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Recombinant Proteins; Tamoxifen; Trefoil Factor-1; Tumor Suppressor Proteins | 2012 |
Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Drug Synergism; Epigenesis, Genetic; Estradiol; Estrogen Receptor alpha; Female; Gene Expression; Genistein; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Mice; Mice, Nude; Mice, Transgenic; Proliferating Cell Nuclear Antigen; Promoter Regions, Genetic; Tamoxifen; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Reversal of ER-β silencing by chromatin modifying agents overrides acquired tamoxifen resistance.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents, Hormonal; Apoptosis; Azacitidine; Breast Neoplasms; Cell Survival; Chromatin Assembly and Disassembly; Decitabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estrogen Receptor beta; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; MCF-7 Cells; Tamoxifen; Time Factors; Transfection | 2013 |
High-density array analysis of DNA methylation in Tamoxifen-resistant breast cancer cell lines.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Azacitidine; Breast Neoplasms; Cell Line, Tumor; CpG Islands; DNA Methylation; Drug Resistance, Neoplasm; Estrogen Antagonists; Estrogen Receptor alpha; Female; Humans; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Repressor Proteins; Tamoxifen | 2014 |
Induced Tamoxifen Resistance is Mediated by Increased Methylation of E-Cadherin in Estrogen Receptor-Expressing Breast Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Breast Neoplasms; Cadherins; Cell Movement; DNA Methylation; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Nuclear Proteins; Receptors, Estrogen; Tamoxifen; Twist-Related Protein 1 | 2019 |